ANIK
NASDAQ
Biotechnology
$15.10
USD
+$0.48 (+3.28%)
Last close
Market Cap:
$197.19M
Volume:
166.4K
Previous Close
$14.62
Day Range
$14.58 - $15.16
52 Week Range
$7.87 - $16.24
Average Volume (10 Days)
70K
P/E Ratio
0.00
Dividend Yield
0.00%
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 235 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
CEO
Mr. Stephen Griffin
Headquaters
Bedford, MASSACHUSETTS, US
Founded
1985
Employees
235
IMUX
Immunic Inc
$15.30
+1.5%
NBP
NovaBridge Biosciences
$1.64
+2.5%
ARCT
Arcturus Therapeutics Holdings Inc
$6.88
+0.9%
DTIL
Precision BioSciences Inc
$7.29
+8.0%
EQ
Equillium Inc
$3.05
+3.4%